Patient and platelet component factors
| . | All transfusions . | 2-h CCI . | 24-h CCI . |
|---|---|---|---|
| Number of patients | 73 | 73 | 67 |
| Number of transfusions | 2 140 | 1 563 | 731 |
| Mean recipient age, y (SD) | 57.9 (14.3) | 58 (14.3) | 58.8 (14.1) |
| Male sex, n (%) | 15 (20.5) | 15 (20.5) | 15 (22.4) |
| Caucasian, n (%) | 58 (79.5) | 58 (79.5) | 52 (77.6) |
| AML diagnosis, n (%) | 36 (49.3) | 36 (49.3) | 33 (49.3) |
| Allogeneic HSCT, n (%) | 30 (41.1) | 30 (41.1) | 25 (37.3) |
| Autologous HSCT, n (%) | 2 (2.8) | 2 (2.8) | 2 (3) |
| Median cPRA (IQR) | 88 (60-98) | 89 (68-99) | 88 (58-99) |
| Median cumulative MFI (IQR) | 531 (92-1 736) | 522 (85-1 653) | 531 (66-2 366) |
| Mean CCI (SD) | 12 259 (12 310) | 13 795 (12 196) | 6 237 (10 822) |
| Median spleen size, cm (IQR) | 14 (10.6-17.9) | 14.7 (10.4-18) | 14.7 (11.3-17.9) |
| Major or minor bleeding, n (%) | 166 (7.8) | 114 (7.3) | 101 (13.8) |
| Any transfusion reaction, n (%) | 104 (4.9) | 77 (4.9) | 38 (5.2) |
| Fever/infection/sepsis, n (%) | 247 (12.1) | 143 (9.6) | 100 (13.9) |
| Mean pretransfusion ANC (SD) | 1.38 (3.09) | 1.38 (3.2) | 1.95 (4.23) |
| Major/bidirectional ABO incompatibility, n (%) | 820 (38.3) | 624 (39.9) | 274 (37.5) |
| Pathogen inactivation, n (%) | 284 (13.4) | 208 (13.5) | 92 (12.7) |
| PAS storage solution, n (%) | 978 (46.2) | 729 (47.2) | 317 (43.8) |
| Mean time since first HLA product, days (SD) | 142 (195) | 140 (191) | 118 (195) |
| Proportion HLA-selected to RAP | 0.6 | 0.6 | 0.5 |
| Antibiotic use, n (%) | 744 (34.8) | 510 (32.6) | 319 (43.6) |
| DIC/TMA, n (%) | 86 (4.0) | 66 (4.2) | 34 (4.7) |
| Median number of prior pregnancies (IQR) | 3 (2-4) | 3 (2-4) | 2 (2-4) |
| Prior myeloablative conditioning, n (%) | 189 (33) | 125 (32) | 55 (25.2) |
| History of acute GVHD, n (%) | 312 (14.6) | 219 (14) | 101 (13.8) |
| . | All transfusions . | 2-h CCI . | 24-h CCI . |
|---|---|---|---|
| Number of patients | 73 | 73 | 67 |
| Number of transfusions | 2 140 | 1 563 | 731 |
| Mean recipient age, y (SD) | 57.9 (14.3) | 58 (14.3) | 58.8 (14.1) |
| Male sex, n (%) | 15 (20.5) | 15 (20.5) | 15 (22.4) |
| Caucasian, n (%) | 58 (79.5) | 58 (79.5) | 52 (77.6) |
| AML diagnosis, n (%) | 36 (49.3) | 36 (49.3) | 33 (49.3) |
| Allogeneic HSCT, n (%) | 30 (41.1) | 30 (41.1) | 25 (37.3) |
| Autologous HSCT, n (%) | 2 (2.8) | 2 (2.8) | 2 (3) |
| Median cPRA (IQR) | 88 (60-98) | 89 (68-99) | 88 (58-99) |
| Median cumulative MFI (IQR) | 531 (92-1 736) | 522 (85-1 653) | 531 (66-2 366) |
| Mean CCI (SD) | 12 259 (12 310) | 13 795 (12 196) | 6 237 (10 822) |
| Median spleen size, cm (IQR) | 14 (10.6-17.9) | 14.7 (10.4-18) | 14.7 (11.3-17.9) |
| Major or minor bleeding, n (%) | 166 (7.8) | 114 (7.3) | 101 (13.8) |
| Any transfusion reaction, n (%) | 104 (4.9) | 77 (4.9) | 38 (5.2) |
| Fever/infection/sepsis, n (%) | 247 (12.1) | 143 (9.6) | 100 (13.9) |
| Mean pretransfusion ANC (SD) | 1.38 (3.09) | 1.38 (3.2) | 1.95 (4.23) |
| Major/bidirectional ABO incompatibility, n (%) | 820 (38.3) | 624 (39.9) | 274 (37.5) |
| Pathogen inactivation, n (%) | 284 (13.4) | 208 (13.5) | 92 (12.7) |
| PAS storage solution, n (%) | 978 (46.2) | 729 (47.2) | 317 (43.8) |
| Mean time since first HLA product, days (SD) | 142 (195) | 140 (191) | 118 (195) |
| Proportion HLA-selected to RAP | 0.6 | 0.6 | 0.5 |
| Antibiotic use, n (%) | 744 (34.8) | 510 (32.6) | 319 (43.6) |
| DIC/TMA, n (%) | 86 (4.0) | 66 (4.2) | 34 (4.7) |
| Median number of prior pregnancies (IQR) | 3 (2-4) | 3 (2-4) | 2 (2-4) |
| Prior myeloablative conditioning, n (%) | 189 (33) | 125 (32) | 55 (25.2) |
| History of acute GVHD, n (%) | 312 (14.6) | 219 (14) | 101 (13.8) |
n shown for each variable unless otherwise denoted; 20 of 73 patients had splenomegaly, accounting for 472 transfusions. Antibiotics included vancomycin, linezolid, and amphotericin. Proportion HLA-selected to RAP denotes the proportion of prior transfusions received by each patient in the study period that were HLA-selected products (excluding the first transfusion).
AML, acute myeloid leukemia; ANC, absolute neutrophil count; cPRA, calculated panel reactive antibody; DAT, direct antiglobulin test; DIC, disseminated intravascular coagulation; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplant; IQR, interquartile range; RAP, randomly selected apheresis platelets; SD, standard deviation; TMA, thrombotic microangiopathy.